CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
OBJECTIVE
To assess the efficacy and toxicity of chemotherapy consisting of cyclophosphamide, doxorubicin (Adriamycin), vincristine, and dexamethasone (CHOD) plus bis-chloronitrosourea (BCNU), cytosine arabinoside, and methotrexate (BVAM) followed by whole-brain irradiation (WBRT) for patients with primary central nervous system lymphoma (PCNSL).


METHODS
Patients 70 years old and younger with newly diagnosed, biopsy-proven PCNSL received one cycle of CHOD followed by two cycles of BVAM. Patients then received WBRT, 30.6 Gy, if a complete response was evoked, or 50.4 Gy if the response was less than complete; both doses were given in 1.8-Gy daily fractions. The primary efficacy endpoint was 1-year survival.


RESULTS
Thirty-six patients (19 men, 17 women) enrolled between 1995 and 2000. Median age was 60.5 years (range, 34 to 69 years). Thirty (83%) patients had baseline Eastern Cooperative Oncology Group performance scores of 0 to 1. All 36 patients were eligible for survival and response evaluations. Median time to progression was 12.3 months, and median survival was 18.5 months. The percentages of patients alive at 1, 2, and 3 years were 64%, 36%, and 33%, respectively. The best response was complete response in 10 patients and immediate progression in 7 patients. Ten (28%) patients had at least one grade 3 or higher neurologic toxicity.


CONCLUSIONS
This regimen did improve the survival of PCNSL patients but also caused substantial toxicity. The improvement in survival is less than that reported with high-dose methotrexate-based therapies.
Laack
Nadia N
NN
Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
O'Neill
Brian Patrick
BP
Ballman
Karla V
KV
O'Fallon
Judith Rich
JR
Carrero
Xiomara W
XW
Kurtin
Paul J
PJ
Scheithauer
Bernd W
BW
Brown
Paul D
PD
Habermann
Thomas M
TM
Colgan
Joseph P
JP
Gilbert
Mark R
MR
Hawkins
Roland B
RB
Morton
Roscoe F
RF
Windschitl
Harry E
HE
Fitch
Tom R
TR
Pajon
Eduardo R
ER
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D003131:Combined Modality Therapy / Q000379:methods; D016371:Cranial Irradiation / Q000009:adverse effects / Q000379:methods*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D003561:Cytarabine; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D002330:Carmustine; D008727:Methotrexate
J Clin Oncol. 2003 Jan 15;21(2):266-72
12525518
J Clin Oncol. 2006 Oct 1;24(28):4570-4
17008697
Neurology. 2004 Feb 24;62(4):548-55
14981169
Cancer. 2008 Apr 15;112(8):1812-20
18318432
Clin Oncol (R Coll Radiol). 2005 May;17(3):185-91
15901003
Neurology. 1994 Sep;44(9):1721-7
7936304
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):408-13
16198065
J Clin Oncol. 2000 Sep;18(17):3144-50
10963643
Neurology. 2004 Feb 24;62(4):544-7
14981168
Leuk Lymphoma. 2006 Dec;47(12):2449-52
17169791
J Clin Oncol. 1998 Apr;16(4):1561-7
9552066
J Clin Oncol. 2003 Mar 15;21(6):1044-9
12637469
Neuro Oncol. 1999 Jul;1(3):196-203
11554388
Expert Rev Anticancer Ther. 2001 Oct;1(3):382-94
12113105
J Clin Oncol. 1998 Mar;16(3):859-63
9508166
J Clin Oncol. 2002 Dec 15;20(24):4643-8
12488408
J Clin Oncol. 2002 Jan 1;20(1):231-6
11773174
J Clin Oncol. 2003 Dec 15;21(24):4483-8
14597741
Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1429-39
16863926
Clin Cancer Res. 2002 Jun;8(6):1702-9
12060607
Int J Radiat Oncol Biol Phys. 1992;23(1):9-17
1572835
JAMA. 1993 May 12;269(18):2386-91
8479064
Arch Neurol. 2003 Apr;60(4):563-8
12707070
Neurology. 2002 May 28;58(10):1513-20
12034789
Biometrics. 1982 Mar;38(1):143-51
7082756
Semin Oncol. 2004 Oct;31(5):684-92
15497122
Cancer. 2002 Oct 1;95(7):1504-10
12237919
Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):559-63
10078637
J Clin Oncol. 2003 Nov 15;21(22):4151-6
14615443
Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):457-64
11380234